FDA
-
-
-
-
-
-
-
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
-
-
-
-
-
-
-
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
-
-
-
-
-
-
-
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
-
-
-
-
-
-
-
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
-
-
-
-
-
-
-
Gain Therapeutics to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

